Newborn calf serum is the liquid portion of clotted blood taken from healthy, slaughtered bovine calves younger than 20 days that have been confirmed to be suitable for human consumption. It is widely used in industrial and academic research. It is one of the supplements used as a basal growth medium in cell culture. It plays a major role in stem cell research and the research of veterinary and human vaccines.
Fetal bovine serum and newborn calf serum both contain many of the same nutrients; however, newborn calf serum contains relatively more protein such as albumin and globulins. Bovine calves which are under 14 days old and healthy are inspected and collected for the production of newborn calf serum under strict collection and processing criteria. Newborn calf serum has applications in biotechnology research and development, stem cell research, cloning, animal diagnostic, in vitro fertilization, biopharmaceuticals, gene therapy, synthetic proteins, etc.
Increasing collaboration among the market players in order to expand their portfolio is expected to drive the growth of the global newborn calf serum market. For instance, in June 28, 2022, Terumo Blood and Cell Technologies, a medical technology company, collaborated with GenCure, a pharmaceutical company, to expand their manufacturing solutions for cell and gene therapy. The collaboration will utilize expertise from Terumo and GenCure to form a reference manufacturing center for BioBridge Global, provide a wide range of blood, cell and tissue products to customers worldwide. Through this reference site, GenCure will deliver solution for cell and gene therapy developers. Cell and gene therapy uses cell culture techniques and new born calf serum is used for growing different cell lines.
Market players are moving towards advance cell manufacturing technologies, which is expected to drive the global newborn calf serum market growth. For instance, in 2017, the Centre for Advanced Therapeutic Cell Technologies (CATCT) at MaRS, a nonprofit corporation found advanced manufacturing solutions to industrialize the cell manufacturing process to meet the needs of cell therapy companies around the world. Newborn calf serum is key ingredient in growing Vero cell lines, the development of cell manufacturing will increase the use of newborn calf serum.
Conferences have been organized and market players are participating on a large scale for discussion and talking about the rapid development in cell line and cell culture, which is expected to drive the global newborn calf serum market growth. For instance, in 2021, BioProcess International U.S. West conference held virtual event, highlighted its presentation on cell lines stability with different media, boom in cell-line development etc., they focused on increasing the awareness among market players about cell culture techniques, through which it is expected the use of calf serum will increase in market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients